大行評級|建銀國際:下調康方生物目標價至85港元 維持“跑贏大市”評級
建銀國際發表報吿指,對康方生物AK112的海外臨牀試驗持更加樂觀的態度。2月25日,公司美國合作伙伴Summit Therapeutics宣佈,將啟動AK112在美國的臨牀試驗。AK112是康方生物已獲批的針對肺部相關癌症的雙特異性抗體,此次試驗將與輝瑞的多種抗體藥物偶聯物進行聯合療法試驗。與早先披露的信息一致,Summit Therapeutics計劃發佈AK112聯合化療的美國三期臨牀試驗結果,用於治療曾接受EGFR-TKI療法的非小細胞肺癌患者。建銀國際對該股目標價從86港元下調至85港元,以反映對收入的較低預測和淨虧損的較高預測。然而,該行仍視該股為首選,維持“跑贏大市”評級,原因包括前兩個關鍵雙特異性抗體已納入國家醫保藥品目錄,有望推動銷售量增長;豐富的新藥研發管線和良好的臨牀進展;AK112與Summit Therapeutics合作的全球三期臨牀試驗進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.